🗞️ Why in News
On July 16, 2026, NITI Aayog, working through the NITI Frontier Tech Hub (FTH), released a landmark roadmap titled “Building India as a Leading BioEconomy Powerhouse”. The report was launched by the Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh, at the National Media Centre, New Delhi. It sets out how India can grow its bioeconomy to roughly USD 691 billion by 2035 and place the country among the world’s top three biotechnology powers.
What the Roadmap Proposes
India’s bioeconomy covers all economic activity derived from biological resources and processes, spanning biopharmaceuticals, industrial biotechnology, bio-agriculture, bio-based fuels and bio-services. The roadmap positions this sector as a core engine of Atmanirbhar Bharat and the Viksit Bharat 2047 vision.
The document lays out a two-stage ambition. In the near term, it aims to lift the bioeconomy to about USD 691 billion by 2035. In the longer term, it projects a scale of roughly USD 2.6 trillion by 2047, which would be about 8 to 10 per cent of GDP. Alongside this, it targets the creation of more than 30 million high-value jobs and the emergence of India as one of the world’s three leading biotech nations.
The BioEconomy Growth Fund
A central recommendation is a dedicated Rs 50,000 crore BioEconomy Growth Fund (2026 to 2035). The fund is designed to bridge the persistent lab-to-market gap, where promising research fails to reach commercial scale for want of patient, risk-tolerant capital. The roadmap pairs this with Production Linked Incentive (PLI) style incentives to reward manufacturing and value addition inside India rather than the export of raw intellectual property.
The Six National BioMissions
The roadmap organises delivery around six mission-mode programmes, each targeting a frontier where India has scientific strength or strategic need.
| BioMission | Focus Area | Strategic Relevance |
|---|---|---|
| Gene and Cell Therapies | Advanced curative medicine | Affordable treatment for genetic and chronic disease |
| Climate-Resilient Agriculture | Stress-tolerant crops | Food security under climate stress |
| Synthetic Biology | Engineered biological systems | High-value industrial and pharma products |
| Disease Surveillance | Pathogen and outbreak monitoring | Pandemic preparedness and biosecurity |
| Marine Biotechnology | Ocean-derived bioresources | Blue economy and novel compounds |
| Next-Generation Biopharmaceuticals | Biologics and vaccines | Reduced import dependence in medicine |
Each BioMission is intended to run in mission mode with clear targets, dedicated funding lines and a mix of public research institutions and private industry.
Link to the BioE3 Policy
The roadmap builds directly on the BioE3 Policy (2024), which stands for Biotechnology for Economy, Environment and Employment. BioE3 shifted Indian biotech strategy toward high-performance biomanufacturing and a circular, sustainable model. The new roadmap operationalises that policy by attaching financing, missions and regulatory reform to its objectives.
Reforms and Enablers
Beyond funding, the roadmap stresses that money alone will not deliver scale. It calls for streamlined regulatory and approval pathways, a stronger intellectual property (IP) regime, and better coordination among the Department of Biotechnology, ministries and state governments. It also flags the need for skilled talent, shared research infrastructure and bio-foundries that let start-ups prototype at low cost.
The report frames the bioeconomy as a rare convergence of economic growth, environmental sustainability and mass employment, which is precisely the promise embedded in the BioE3 acronym.
UPSC Relevance
GS Paper 3: Science and Technology, developments and applications; Indian economy, mobilisation of resources, growth and employment; issues relating to intellectual property rights.
Prelims pointers:
- Roadmap name: “Building India as a Leading BioEconomy Powerhouse”, released by NITI Aayog via the NITI Frontier Tech Hub.
- Target: about USD 691 billion by 2035; roughly USD 2.6 trillion by 2047 (8 to 10 per cent of GDP).
- Proposed Rs 50,000 crore BioEconomy Growth Fund (2026 to 2035).
- Six National BioMissions, including synthetic biology and marine biotechnology.
- Builds on the BioE3 Policy (2024): Biotechnology for Economy, Environment and Employment.
Mains question: India’s bioeconomy roadmap promises a USD 691 billion sector by 2035. Examine the structural reforms in finance, regulation and intellectual property needed to bridge the lab-to-market gap and realise this potential.
📌 Facts Corner, Knowledgepedia
- Bioeconomy refers to economic activity based on renewable biological resources and biotechnological processes, cutting across health, agriculture, industry and energy.
- India’s bioeconomy has grown rapidly on the strength of vaccines, biosimilars and bio-services, with vaccine manufacturing a global standout.
- The BioE3 Policy was approved by the Union Cabinet in 2024 and promotes high-performance biomanufacturing.
- The NITI Frontier Tech Hub (FTH) is NITI Aayog’s unit for emerging technologies such as biotech, quantum and advanced materials.
- India’s stated climate goal of net zero by 2070 intersects with bio-based fuels and materials that can lower industrial emissions.
Sources: NITI Aayog roadmap release “Building India as a Leading BioEconomy Powerhouse” (July 16, 2026); Press Information Bureau; Ministry of Science and Technology; BioE3 Policy 2024 documents.
Source: NITI Aayog Bioeconomy Roadmap: India as a BioEconomy Powerhouse by 2035 — Ujiyari.com | Free UPSC & State PCS Current Affairs
